Loading...
OTCM
LOBEF
Market cap14mUSD
Jul 09, Last price  
0.07USD
1D
2.81%
1Q
41.42%
IPO
-84.39%
Name

Lobe Sciences Ltd

Chart & Performance

D1W1MN
OTCM:LOBEF chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
61.69%
Rev. gr., 5y
-29.35%
Revenues
0k
-100.00%
0000000773,792884,83700840,534136,2050
Net income
-4m
L+0.08%
-91,001-93,104-134,000-170,839-55,972-51,795-148,000-754,000-3,436,000-9,658,000-12,253,000-4,707,000-4,421,000-4,424,660
CFO
-1m
L+206.33%
-44,924-84,704-126,342-106,202-59,767-44,843-51,934-2,043,609-1,222,417-5,037,358-2,730,729-1,718,644-462,293-1,416,163
Earnings
Dec 28, 2026

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Lobe Sciences Ltd. is a life sciences company focused on researching and advancing psychedelic-based medicines. Their primary therapeutic development involves psilocybin-derived treatments combined with N-acetylcysteine, specifically for addressing mild traumatic brain injuries (mTBI) and post-traumatic stress disorder (PTSD). Additionally, they engineer specialized devices aimed at enhancing the efficiency of drug administration. This organization, headquartered in Vancouver, Canada, underwent a name change from Greenstar Biosciences Corp. to Lobe Sciences Ltd. in November 2020.
IPO date
Jun 19, 2012
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2025‑082024‑082023‑082022‑082021‑082020‑082019‑082017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT